ALCAR.PA stock trades at €0.099 pre-market on EURONEXT after a sharp multi-period decline, presenting an oversold bounce candidate for short-term traders. Volume 807,348 shares is in line with the 30-day average 797,166, suggesting market attention. We outline technical triggers, fundamental red flags, and a priced risk plan for an oversold bounce strategy ahead of any company updates or sector moves.
Pre-market snapshot for ALCAR.PA stock
Carmat SA (ALCAR.PA) opens pre-market at €0.099 on EURONEXT in Europe with a day range €0.097–€0.11 and market cap €6,361,146.00. Volume at 807,348 versus average 797,166 gives a relative volume of 1.01, showing tradable liquidity for a micro-cap. The last formal earnings notice was 09 Mar 2026, and EPS stands at -1.15, underlining ongoing operating losses.
Why ALCAR.PA stock looks oversold
ALCAR.PA stock is deeply beaten: YTD -91.16% and 3M -67.70%, and the current price sits below the 50-day average (€0.15) and far below the 200-day average (€0.59). That gap signals oversold conditions versus recent trading norms. The year low is €0.085 and a short-term rebound often starts near multi-month lows for small caps.
Technical bounce triggers for ALCAR.PA stock
Short-term bounce triggers are a volume lift above 1.0x average and a move back over intraday €0.11 with follow-through. Day support is near €0.097 and failure below €0.085 would invalidate the bounce setup quickly. Given low absolute price, use tight position sizing and a stop-loss to limit dilution and liquidity risk.
Fundamentals and valuation for ALCAR.PA stock
Fundamentals remain weak: negative EPS -1.15, PE not meaningful, and book value per share -2.24. Price-to-sales is 0.91 while EV/Sales is 8.49, reflecting a high enterprise value relative to revenue. Cash per share €0.21 and current ratio 1.70 give short-term coverage, but inventory days and operating cash flow are stretched—clear operational risks for investors.
Meyka AI grading and forecast for ALCAR.PA stock
Meyka AI rates ALCAR.PA with a score of 72.88 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 comparison, sector and industry peers, financial growth, key metrics, and analyst inputs. Meyka AI’s forecast model projects a near-term bounce target of €0.18 (implied +81.82% vs €0.099) and a 12-month recovery target of €0.60 (implied +506.06%). Forecasts are model-based projections and not guarantees.
Risk checklist and trade plan for ALCAR.PA stock
Primary risks are continued cash burn, clinical or regulatory setbacks, and equity dilution given small market cap. For an oversold bounce trade, consider a small position size, a stop below €0.085, and target levels at €0.18 then €0.30 for staged profit-taking. Use trade management and expect high volatility in this healthcare medical-devices micro-cap.
Final Thoughts
ALCAR.PA stock at €0.099 fits a disciplined oversold bounce strategy for traders who accept micro-cap and clinical risks. Short-term trade logic is simple: volume confirmation above average and a clean move above €0.11 can validate a first entry toward the Meyka AI short-term target €0.18 (+81.82%). Longer-term recovery to €0.60 assumes operational improvements and funding clarity; that projection implies large upside but comes with high execution and clinical risk. Meyka AI rates the name 72.88/100 (B+, BUY) based on sector, metrics, and growth trends, but this grade is informational and not investment advice. Monitor upcoming company announcements, EURONEXT liquidity, and healthcare sector momentum. For an active trade, size positions conservatively and set a stop below €0.085; check the Carmat company page and real-time updates on our Meyka stock page. Recent industry calendars and comparators are listed on Investing.com for reference source and comparative quotes are available from Investing.com tools source.
FAQs
Is ALCAR.PA stock a buy for a short-term bounce?
ALCAR.PA stock shows a short-term bounce setup if volume climbs above 807,348 and price clears €0.11. Trade small, use a tight stop under €0.085, and expect high volatility. This is a tactical trade idea, not a recommendation.
What are the main risks for ALCAR.PA stock?
Key risks for ALCAR.PA stock include cash burn, clinical or regulatory setbacks, potential dilution, and thin market cap liquidity on EURONEXT. These factors can reverse any oversold bounce quickly.
What targets does Meyka AI give for ALCAR.PA stock?
Meyka AI’s model projects a near-term target €0.18 (+81.82%) and a 12‑month target €0.60 (+506.06%) versus the current €0.099. Forecasts are model-based and not guarantees.
How does sector data affect ALCAR.PA stock?
ALCAR.PA stock operates in Healthcare Medical‑Devices where peers show stronger margins and higher P/E. Sector pressure or regulatory news can amplify moves; use sector signals to time entries and exits.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)